Dermatology · Pasadena, TX
NPI
1760484349
Since 2005
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
4419 Crenshaw Rd
Pasadena, TX, 77504
Phone (281) 991-5944
Groups this clinician bills Medicare through
Medicare paid, 2024
$178K
3,474 services
Medicare patients, 2024
725
Average age 75
Drug cost, 2024
$807K
1,995 prescriptions
Company payments, 2025
$4,615
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Wendy C Magee was code 17003 (destruction skin lesion), 1,070 times for 178 patients. In total Wendy C Magee billed 3,474 services in 55 codes, and Medicare paid $178K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-02-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 1,070 | 178 | $4.98 | $5,328 |
| 99213 Office E&M - Established | Office | 767 | 531 | $68.81 | $53K |
| 17110 Destruction Skin Lesion | Office | 430 | 342 | $80.96 | $35K |
| 17000 Destruction Skin Lesion | Office | 306 | 244 | $36.86 | $11K |
| 11102 Skin Biopsy | Office | 241 | 216 | $58.73 | $14K |
| 99214 Office E&M - Established | Office | 139 | 130 | $87.64 | $12K |
| 99203 Office E&M - New | Office | 100 | 100 | $79.27 | $7,927 |
| 17111 Destruction Skin Lesion | Office | 49 | 39 | $98.18 | $4,811 |
| 17004 Destruction Skin Lesion | Office | 37 | 27 | $133.48 | $4,939 |
| 11103 Skin Biopsy | Office | 30 | 28 | $37.30 | $1,119 |
| 12032 Wound Repair - All Levels | Office | 26 | 25 | $221.72 | $5,765 |
| 12031 Wound Repair - All Levels | Office | 25 | 25 | $205.48 | $5,137 |
| 69100 Other Organ Systems | Office | 17 | 17 | $64.67 | $1,099 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 16 | 12 | $0.72 | $11.58 |
| 11900 Skin | Office | 16 | 12 | $36.97 | $591 |
By year: 2022 $187K for 3,728 services; 2023 $172K for 3,470 services; 2024 $178K for 3,474 services.
Medicare prescription drug claims, 2024
In 2024, the drug Wendy C Magee prescribed most often to Medicare patients was Doxycycline Hyclate, with 180 prescriptions and refills. In total Wendy C Magee wrote 1,995 Medicare prescriptions that cost $807K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Doxycycline Hyclate Generic | 180 | 221 | 57 | $2,359 |
| Ketoconazole Generic | 175 | 190 | 100 | $3,201 |
| Fluorouracil Generic | 168 | 168 | 148 | $11K |
| Clobetasol Propionate Generic | 157 | 166 | 92 | $8,802 |
| Triamcinolone Acetonide Generic | 152 | 176 | 122 | $2,130 |
| Mupirocin Generic | 88 | 88 | 49 | $561 |
| Hydrocortisone Generic | 85 | 85 | 64 | $300 |
| Betamethasone Dipropionate Generic | 67 | 71 | 44 | $2,475 |
| Terbinafine Hcl Generic | 65 | 87 | 38 | $430 |
| Ciclopirox Generic | 64 | 66 | 28 | $1,889 |
| Metronidazole Generic | 57 | 60 | 35 | $2,195 |
| Otezla Apremilast | 47 | 47 | Under 11 | $224K |
| Valacyclovir Valacyclovir Hcl | 47 | 63 | 24 | $1,489 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 36 | 36 | 14 | $250 |
| Cephalexin Generic | 31 | 31 | 26 | $124 |
Brand drugs: 139 claims; generic drugs: 1,856 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Wendy C Magee $4,615 ($4,615 in general payments such as food, travel and fees) from 24 companies. The largest payer was Abbvie Inc. with $590.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 36 | $590 |
| Janssen Biotech, Inc. JNJ | 20 | $503 |
| Genzyme Corporation SNY | 14 | $492 |
| Novartis Pharmaceuticals Corporation NVS | 18 | $468 |
| UCB, Inc. UCB.BR | 16 | $418 |
| LEO Pharma Inc. | 18 | $265 |
| Pfizer Inc. PFE | 25 | $262 |
| Arcutis Biotherapeutics, Inc. ARQT | 18 | $261 |
| Incyte Corporation INCY | 10 | $222 |
| Regeneron Healthcare Solutions, Inc. REGN | 8 | $218 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.